Abstract: A method of making a temporary medical electrical lead for pacing or defibrillating a heart of a patient.

Abstract: An implantable device for reducing restenosis includes a structure including a polyamino acid component, wherein the polyamino acid component can be in the form of a coating or a film on the structure or it can be an integral part of the structure.

Abstract: Methods, compositions and devices for inhibiting restenosis are provided. Specifically, molecular chaperone inhibitor compositions and medical devices useful for the site specific delivery of molecular chaperones are disclosed. In one embodiment the medical device is a vascular stent coated with a molecular chaperone inhibitor selected from the group consisting of geldanamycin, herbimycin, macbecin and derivatives and analogues thereof. In another embodiment an injection catheter for delivery an anti-restenotic effective amount of geldanamycin to the adventitia is provided.

Abstract: The present invention provides a medical device that includes a carrier and a polynucleotide, where the carrier has a surface that includes a polymer with which the polynucleotide is associated. In another aspect, the present invention provides a medical device that includes a carrier and a cell that expresses an antimicrobial peptide, where the carrier has a surface that includes a polymer with which the cell is associated. The present invention further provides methods of making and using medical devices that include a carrier and a polynucleotide or a cell.

Abstract: Biological tissue adhesives can be in the form of a gel that is applied to biological tissue as a “glue” or supported on a backing or substrate to form an article such as a self-sticking patch or pad. Adhesive articles can include such biological tissue adhesives or be functionalized to directly adhere to biological tissue without the biological adhesive.

Abstract: A temporary cardiac electrical stimulating lead is disclosed having a stimulating electrode mounted in or on an electrode mounting pad disposed at a distal end of the lead, the pad having a biodegradable adhesive disposed thereon and/or therewithin. The adhesive, and preferably also the electrode mounting pad, are capable of biodegradably dissolving over time in human body fluids. The adhesive permits the electrode mounting pad to be attached to a patient's epicardium without the use of sutures, or with fewer sutures than have heretofore been required to suitably affix an electrode mounting pad to a patient's heart. In a preferred embodiment, when the lead body is pulled away from the electrode mounting pad and removed from a patient, any portion of the electrode mounting pad and the adhesive remaining within the patient dissolves over time and disappears.

Abstract: A temporary cardiac electrical stimulating lead comprises a stimulating electrode mounted in or on a biodegradable electrode mounting pad disposed at a distal end of the lead. The electrode mounting pad is capable of biodegradably dissolving over time in human body fluids and is loaded with a drug for therapeutically treating a medical condition of a patient's heart. The electrode mounting pad may be loaded with any of a variety of different drugs, such anti-arrhythmia or anti-inflammatory drugs. When the lead body is pulled away from the electrode mounting pad and removed from the patient, any portion of the electrode mounting pad remaining within the patient dissolves over time and disappears.

Abstract: A temporary cardiac electrical stimulating lead is disclosed having a stimulating electrode mounted in or on a biodegradable electrode mounting pad disposed at a distal end of the lead. The electrode mounting pad is capable of biodegradably dissolving over time in human body fluids and is loaded with a drug for therapeutically treating a medical condition of a patient's heart. The electrode mounting pad may be loaded with any of a variety of different drugs, such anti-arrhythmia or anti-inflammatory drugs. When the lead body is pulled away from the electrode mounting pad and removed from the patient, any portion of the electrode mounting pad remaining within the patient dissolves over time and disappears.

Abstract: A temporary cardiac electrical stimulating lead is disclosed where the lead body thereof may be removed from inside a patient through the application of a simple pulling force exerted on its proximal end. An electrode mounting pad is located at the distal end of the lead and has a stimulating electrode mounted thereon or therein. A distal end of the electrical conductor may serve as the stimulating electrode. The electrode mounting pad is preferably capable of biodegradably dissolving or otherwise dissociating over time in human body fluids. Thus, the lead body may be detached from the electrode mounting pad through the application of a simple pulling force and removed from the patient while the electrode mounting pad remains within the patient and dissolves or otherwise dissociates over time.

Abstract: Biocompatible metallic medical devices having silanized surfaces coupled to nucleophile residues that release sustained, therapeutic amounts of nitric oxide to specific sites within a mammalian body are provided. Additionally, the biocompatible metallic medical devices can also be provided with anti-thrombogenic, lubricious coatings that release sustained, therapeutic amounts of nitric oxide. Moreover, the silanized metallic devices are surprisingly durable when exposed to harsh chemical methods often needed to bind nitric oxide-releasing functional groups to nucleophile residues. Furthermore, methods are provided for producing stable, silanized, sustained nitric oxide-releasing metallic medical devices.

Abstract: Biocompatible metallic medical devices having silanized surfaces coupled to nucleophile residues that release sustained, therapeutic amounts of nitric oxide to specific sites within a mammalian body are provided. Additionally, the biocompatible metallic medical devices can also be provided with anti-thrombogenic, lubricious coatings that release sustained, therapeutic amounts of nitric oxide. Moreover, the silanized metallic devices are surprisingly durable when exposed to harsh chemical methods often needed to bind nitric oxide-releasing functional groups to nucleophile residues. Furthermore, methods are provided for producing stable, silanized, sustained nitric oxide-releasing metallic medical devices.

Abstract: Methods for making bioprosthetic devices made of collagen-based material having collagen amine groups and collagen carboxyl groups are provided. The methods include blocking at least a portion of the collagen amine groups with a blocking agent, activating at least a portion of the collagen carboxyl groups after blocking at least a portion of the collagen amine groups to form activated carboxyl groups, and contacting the activated collagen carboxyl groups with a polyfunctional spacer to crosslink the collagen-based material.

Abstract: Bioprosthetic devices made of collagen-based material having collagen amine groups and collagen carboxyl groups are provided as well as methods for their formation. The methods comprise combining an epoxy functionalized crosslinking agent with the collagen-based material in an aqueous medium at an acidic pH to react a portion of the collagen carboxyl groups with the epoxy functionalized crosslinking agent to form crosslinked collagen-based material comprising residual collagen carboxyl groups.

Abstract: A method for making a medical device having a biomolecule immobilized on a substrate surface is provided. The method includes coating the substrate surface with an amino-functional polysiloxane; and contacting the amino-functional polysiloxane coated surface with a biomolecule under conditions effective to immobilize the biomolecule.

Abstract: A medical device having a surface graft matrix comprising carboxyl-functional groups located on the device, the surface graft matrix comprising an outer portion; and one or more biomolecules covalently coupled to the surface graft matrix, wherein a majority of the biomolecules are located in the outer portion of the surface graft matrix. The surface graft matrix can also be loaded with a pharmaceutical agent.

Abstract: To minimize the incidence and consequences of device related infection that occur after prosthetics implants of neuro-muscular stimulating devices, an infection resistant intra-muscular lead has been developed and is disclosed herein. Infection incidence has been decreased by using biomaterials able to release antibacterial drugs (gentamicin) at a controlled rate for the first 3-6 weeks after implant.

Abstract: A medical device having a surface graft matrix comprising carboxyl-functional groups located on the device, the surface graft matrix comprising an outer portion; and one or more biomolecules covalently coupled to the surface graft matrix, wherein a majority of the biomolecules are located in the outer portion of the surface graft matrix. The surface graft matrix can also be loaded with a pharmaceutical agent.

Abstract: A medical article having a metal or glass surface with the surface having an adherent coating of improved biocompatibility. The coating is made by first applying to the surface an silane compound having a pendant vinyl functionality such that the silane adheres to the surface and then, in a separate step, forming a graft polymer on the surface with applied vinylsilane such that the pendant vinyl functionality of the vinylsilane is incorporated into the graft polymer by covalent bonding with the polymer. Biomolecules may then be covalently attached to the base layer.

Abstract: A method of treating a patient with a medical device having immobilized heparin on a blood-contacting surface in which the covalently attached heparinized surface is provided with an adsorbed protein which may be activated by the immobilized heparin to block the coagulation of fibrinogen. Antithrombin III is the preferred adsorbed protein. The adsorbed protein is maintained on the immobilized heparin surface until the medical device is placed into contact with the patient's blood. When in contact with the patient's blood, the adsorbed protein will prevent initial thrombin formation at the biomaterial-blood interface. The preadsorption of ATIII is accomplished under conditions advantageous to maximum heparin/ATIII binding. When the preadsorbed surface comes in contact with whole blood, the maximum advantage of prophlactic properties of ATIII/heparin are obtained.

Abstract: To minimize the incidence and consequences of device related infection that occur after prosthetics implants of neuro-muscular stimulating devices, an infection resistant intramuscular lead has been developed. Infection incidence has been decreased by using biomaterials able to release antibacterial drugs (gentamicin) at a controlled rate for the first 3-6 weeks after implant.